Holy Name provides high quality health care across a continuum that encompasses education, prevention, early intervention, comprehensive treatment options, rehabilitation and wellness maintenance. PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach. and BEIJING (September 29, 2020) CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced a restructuring of its partnership with Juventas Cell Therapy Ltd. relating to CNCT19, an investigational CD19 . Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life-threatening diseases. Juventas Therapeutics, Inc. Report issue. This is an introductory text to gene therapy, an expanding area of research with current and potential applications in many different areas of medicine. Tonya Justinger, MBA Director, Finance & Operations at Juventas Therapeutics, Inc. Painesville, Ohio, United States 132 connections In previous clinical studies, JVS-100 has demonstrated the ability to improve micro-vascular blood flow and accelerate dermal wound closure. This new edition of Financial Management of Health Care Organizations offers an introduction to the most-used tools and techniques of health care financial management, including health care accounting and financial statements; managing cash ... Holy Name Medical Center is a fully accredited, not-for-profit healthcare facility based in Teaneck, New Jersey. Juventas Therapeutics Inc Juventas Therapeutics, Inc. operates as a clinical-stage biotechnology company. We had no where to begin. CONTACT: Joseph Barone, 216-273-4000, jbarone@juventasinc.com, © 2017 Juventas Therapeutics • 3615 Superior Avenue, Suite 4403B Cleveland, Ohio 44114 • 216-273-4000 • info@juventasinc.com. Find company research, competitor information, contact details & financial data for Juventas Therapeutics, Inc. of Cleveland, OH. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials. Green Cross provides safe and effective healthcare solutions that address the evolving needs of human health. For profit Phase 1 Phase 2 Phase 3. The company's therapies include non-viral gene therapy which can activate natural processes to repair the body, enabling patients to begin treatment promptly and result in a likelihood of successful treatment. Developer of regenerative therapies intended to treat cardiovascular diseases and ischemic disorders. Green Cross is the largest biopharmaceutical company in South Korea. Juventas Therapeutics, headquartered in Cleveland, OH, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life-threatening diseases. It offers JVS-100, a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein recruiting the body's own stem cells and promoting tissue repair in a range of disease states. Juventas Therapeutics (Juventas Therapeutics) is a Pharmaceutical Company located in Cleveland, OH United States, North America, and was founded in 2007. Found insideFuture volumes in the series will include Heart Failure, Diabetes, Valvular Heart Disease, and more. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Our primary focus is the treatment of non-healing wounds in patients with advanced peripheral artery disease (PAD). The company's lead product, Stromal-cell Derived Factor 1 (SDF-1), has been shown to protect… Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. CLEVELAND, July 23, 2014 /PRNewswire-USNewswire/ -- Juventas Therapeutics, a clinical-stage biotechnology company developing a first-in-class regenerative gene therapy for treatment of heart failure announced adding two industry veterans to its leadership team. This new volume provides new insights with scientific evidence on the uses of medicinal plants in the treatment of certain diseases. Juventas Therapeutics, headquartered in Cleveland, OH, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat lifethreatening diseases. Juventas was founded in 2007 with an exclusive license from the Cleveland Clinic. Juventas Cell Therapy Ltd. is a China-based domestic company located in Tianjin City, China focused on cell therapy. Juventas Therapeutics General Information Description. About Holy Name Medical Center Carlsbad, CA Vice President of Manufacturing . A cardiologist and molecular biologist by training, Dr. Pollman most recently served as Executive Vice President for NaviGate Cardiac Structures, Inc. Found inside – Page 1951Circus Juventas , 2002— , bd . dirs . ... Pharmacology and Exptl . Therapeutics , Am . Heart Assn . ( rsch . investigatorship Ga . affiliate 1987-88 ... Founded: Location: Amount Seeking: About the Company: Juventas Therapeutics is a clinical-stage biotechnology company developing a pipeline of regenerative therapies that activate natural processes to repair the body in order to treat life-threatening diseases. By Mary Vanac Clinical-stage regenerative medicine company Juventas Therapeutics Inc. — a Cleveland Clinic spin-out initially named AcelleRX Therapeutics Inc. — started enrolling patients in a . We are excited to further study the potential for JVS-100 to address this unmet medical need in patients with advanced peripheral artery disease in addition to revascularization.”. © 2021 PitchBook Data. Knotice. Founded and sponsored by the Sisters of St. Joseph of Peace in 1925, the comprehensive 361-bed medical center offers leading-edge medical practice and technology administered in an environment rooted in a tradition of compassion and respect for every patient. Cleveland/Akron, Ohio Area Senior Director Clinical . Juventas Therapeutics starts Phase 1 trial for heart failure By Mary Vanac Clinical-stage regenerative medicine company Juventas Therapeutics Inc.-a Cleveland Clinic spin-off initially named . Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials for . “The Fast Track designation will permit greater access to the FDA for the purpose of expediting the development of JVS-100, including its review and potential approval for this indication.”. For more information about Holy Name Medical Center services, please visit HolyName.org. Here are 62 case histories proving beyond any doubt that Laetrile (Vitamin B17) works in the control of cancer. These are not anecdotal stories or cases of people who never had cancer in the first place. © 2017 Juventas Therapeutics • 3615 Superior Avenue, Suite 4403B Cleveland, Ohio 44114 • 216-273-4000 • info@juventasinc.com. Astellas has already licensed a gene therapy candidate. Description. Our product candidate, JVS-100, is a non-viral gene therapy that . Juventas is the Roman Goddess of youth and rejuvenation. He discovered the SDF-1 molecule's repair potential 16 years ago at the Cleveland Clinic. This book will support your growth as a biotechnology professional. Jobs Jobs. About Juventas Therapeutics, Inc. Juventas Therapeutics, Inc., headquartered in Cleveland, Ohio, is a privately held clinical-stage biotechnology company developing a pipeline of regenerative . Clinical-stage regenerative medicine company Juventas Therapeutics Inc.-a Cleveland Clinic spin-off initially named AccelleRX-has started enrolling patients in a Phase 1 clinical trial to . Dale Sander has joined as Chief Financial Officer. Juventas Therapeutics USA Private Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Juventas Therapeutics is a privately held, clinical-stage biotechnology company developing factor-based regenerative therapies to treat life-threatening dise. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials. All of the authors who have contributed to this book are nationally and internationally recognized experts in cardiovascular disease as it appears in the elderly. This therapeutic approach is based on research originating at the Cleveland Clinic. This novel technology encodes a powerful protein, SDF-1, and allows SironRX to approach wound healing and scar prevention in a unique way - by exploiting the body's own regenerative capabilities, creating an advantage over competitors. Built In is the online community for startups and tech companies. Juventas Therapeutics: Pharmaceutical Company in United States, North America. Juventas Therapeutics is a clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Found inside – Page 538... Pathology, Hygiene, Therapeutics ... with the Accentuation and Etymology of the Terms, ... JUSTICIA ADHATODA , ( after J. Justice , a JUVENTUS ... Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and . Nevertheless such methods find their way into international pharmacopoeias. Thus, the aim of the book is to describe the possibilities of qNMR in pharmaceutical analysis. “The addition of Jim to our Board of Directors and quality new investors to our shareholder base come at a very exciting time for the company,” states Rahul Aras, Ph.D., president and chief executive officer for Juventas. The FDA granted Fast Track designation to JVS-100 for accelerating the healing of chronic ulcers in patients with advanced PAD. For more information, please visit Green Cross’ website at www.greencross.com. Her name is derived from the Latin word 'iuvenis' meaning a young person or juvenile. Juventas Services Limited are an innovative and forward-thinking organisation. For more information, visit www.poscocapital.com. Juventas Therapeutics ViroMed Kuhnil Pharmaceutical; Market segmentation of Angina market: The Report on the world market Angina is divided according to many aspects into respective segments and their sub-segments. Our product candidate, JVS-100, is a non-viral gene therapy that expresses Stromal cell-Derived Factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body's own stem cells to promote tissue repair in a broad range of disease states. In preclinical studies, JVS-100 has shown potential across multiple end-organ systems and may have platform potential in a wide range of indications, including, refractory angina, heart attack, muscle atrophy, dermal scar formation, post-surgical fibrosis, nerve damage and incontinence. Jasper Therapeutics' management team is composed of experienced biopharma industry veterans with extensive track records in drug development and commercialization. Despite the undoubted success of a scientific approach to pharmaceuticals, the last few decades have witnessed a spectacular rise in interest in herbal medicinal products. Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Juventas Therapeutics, headquartered in Cleveland, Ohio, is a privately-held clinical-stage biotechnology company developing therapies for cardiovascular disease. Practical and hands-on, Fungal Secondary Metabolism: Methods and Protocols encourages new investigators to enter the field and expands upon the expertise and range of skills of those already researching fungal natural products. Juventas Therapeutics, (www.juventasinc.com) headquartered in Cleveland, OH, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life . CLEVELAND, OH--(Marketwired Feb 3, 2016) - Juventas Therapeutics, Inc., a clinical-stage gene therapy company, announced that it is enrolling its STOP-PAD trial, a 120-patient, placebo-controlled, randomized double-blinded Phase 2 study evaluating the safety and efficacy of JVS-100, a gene therapy encoding human stromal cell-derived factor-1 (SDF-1), in patients with advanced peripheral artery disease (PAD). Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials. Get the latest business insights from Dun & Bradstreet. Dr. Francis Plat will serve in an advisory capacity as Chief Strategy Officer. Hematological Malignancies & Inherited Blood Disorders The company's therapies include non-viral gene therapy which can activate natural processes to repair the body, enabling patients to begin treatment promptly and result in a likelihood of successful treatment. www.juventasinc.com. Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases. As such has receives consulting fees and stock options. Juventas Therapeutics: Pharmaceutical Company in United States, North America. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Massachusetts and North Carolina. Juventas Therapeutics is a clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Juventas Therapeutics, Inc. Strengthens Leadership Team By Adding Two Industry Veterans. Juventas Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT02115568 Other Study ID Numbers: JTCS-005 : First Posted: April 16, 2014 Key Record Dates: Last Update Posted: April 16, 2014 Last Verified: April 2014 Juventas Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT01082094 Other Study ID Numbers: JTCS-001 : First Posted: March 8, 2010 Key Record Dates: Last Update Posted: June 6, 2012 Last Verified: June 2012 CLAIM THIS BUSINESS. In total, Juventas Therapeutics has raised approximately $45 million. POSCO Capital is the only financial affiliate of POSCO, a Global Fortune 200 Company in Korea. Found insideThis volume contains the invited papers presented as a symposium of The Phytochemical Society of North America which met for its annual meeting at the Asilomar Conference Center, Pacific Grove, California on June 12-16, 1985. (4) Trial conducted by Cleave Therapeutics. The primary endpoints for the study will be wound healing three and six month following the procedure. Our primary focus is the treatment of non-healing wounds in patients with advanced peripheral artery disease (PAD). Subjects will be randomized to receive JVS-100 or placebo, administered via intramuscular injection to the affected limb within 48 hours of the BTK revascularization procedure and again three months later to evaluate the potential of JVS-100 to improve outcomes. There are no jobs right now, but check back soon as we update jobs daily. CONSULTING FEES/HONORARIA: Bayer(SIGNIFICANT), stealth peptides(SIGNIFICANT), tricida(SIGNIFICANT), astra zeneca(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals . Our workflow has solid direction now - we have a process in place the begins with RocketReach and ends with huge contact lists for our sales team..it probably saves Feedtrail about 3 months of work in terms of lead gathering. Regenerative medicine company Juventas Therapeutics Inc. has received regulatory approval to begin a Phase 2 clinical trial of critical limb ischemia patients. Found inside – Page 186The therapeutic success in these clinical trials is commonly determined by ... In the JUVENTAS clinical trial that included 160 patients with severe ... Green Cross Holdings and POSCO Capital led a $7.5 million Series B-2 equity investment that included participation from other new and existing investors. Cleveland, Ohio Global Employees: 6 View Website Overview Overview. Get the full list », Co-Founder, President, Chief Executive Officer & Board Member, Associate Director, Business Development and Analytics, Senior Vice President, Clinical Product Development. Headquartered in Yongin, South Korea, Green Cross specializes in the development and manufacturing of plasma-derivatives, preventive vaccines, recombinant proteins, therapeutic antibodies and cell therapies. For more information about Juventas please visit www.juventasinc.com. The company's lead product, CNCT19, devolved from the CD19 CAR . For more information about Juventas please visit ROCKVILLE, MD. Our primary focus is the treatment of . Juventas Therapeutics, Inc. 6 years 7 months Vice President Clinical Operations Juventas Therapeutics, Inc. Dec 2016 - Dec 2018 2 years 1 month. Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept . Found insideThe impact of Apoptosis, or programmed cell death, is thought to play a crucial role in the development and progression of disease. Juventas Therapeutics's Co-Founder, President and Chief Executive Officer is Rahul Aras. Get the full list », You’re viewing 5 of 11 executive team members. Juventas Therapeutics is a privately held, clinical stage biotechnology company focused on developing non-viral gene therapies to treat advanced cardiovascular diseases. PitchBook is a financial technology company that provides data on the capital markets. Trial conducted by BioInvent. Juventas was founded in 2007 with an exclusive license from the Cleveland Clinic. Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid . In 2007, Juventas Therapeutics became a standalone company. Matthew Pollman, M.D., M.S. Prior to this appointment, he served as the Chief Medical Officer for Juventas Therapeutics and was the Founding CEO, President and Chief Scientific Officer of CV Ingenuity, a clinical stage company acquired by Covidien. . Juventas Therapeutics also expanded its Board of Directors to include James Boland as an independent director. Written by recognized experts, this book aims to provide both basic and advanced knowledge of the newer methodologies being developed and introduced to the clinical arena. CLEVELAND, July 23, 2014 /PRNewswire-USNewswire/ -- Juventas Therapeutics, a clinical-stage biotechnology . Juventas Therapeutics (Juventas Therapeutics) is a Pharmaceutical Company located in Cleveland, OH United States, North America, and was founded in 2007. Aras, Pastore, Fisher and Mr. AuWerter are employees of Juventas Therapeutics, Inc. as such they receive salary and stock options in the company. Company’s lead product candidate, JVS-100, is a non-viral gene therapy undergoing evaluation in clinical studies for the treatment of advanced cardiovascular diseases. Peripheral artery disease is characterized by the narrowing or obstruction of the arteries in the limbs, which diminishes or prevents blood flow resulting in severe pain, limitations in ambulation, non-healing wounds and, in severe cases, the need to amputate the affected limb. For more information visit www.oxfordfinance.com. This volume provides summarized scientific evidence of the different classes of plant-derived phytocompounds, their sources, chemical structures, anticancer properties, mechanisms of action, methods of extraction, and their applications in ... Juventas Therapeutics Healthtech Biotech Location. Juventas Therapeutics 2013 - Present 8 years. Founded: Cleveland OH United States (2007) First Clinical Trial. Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. To JVS-100 for accelerating the healing of chronic ulcers in patients with advanced peripheral artery disease PAD! Partner juventas Completes $ 65 million Financing and Initiates Registration Study for CNCT19 ( CD19 CAR-T.. Treat advanced cardiovascular diseases vast potential in different clinical applications of chronic ulcers in patients advanced... Of Cleveland, OH 44114 get Directions ( 216 ) 445-0830. www.juventasinc.com publishes a wide range of titles that every... Originating at the Cleveland Clinic spin-off initially named, Massachusetts and North Carolina and POSCO Capital specializes in early late... Field of Medical science with vast potential in different clinical applications first clinical trial of critical limb ischemia.! In early to late stage investments though its venture Capital and private sciences! Back soon as we update jobs daily expanded its board of Directors to include James Boland as an independent.... Will recruit additional patients at approximately 25 leading clinical centers in the treatment non-healing! Arida, Chairman ; Matthew Pollman, Chief Medical Officer and 2 others healthcare based... 5 of 10 board members Cross ’ Website at www.greencross.com clinical trial at www.greencross.com ischemia patients micro-vascular blood flow accelerate... 2 ) in combination with rituximab practice juventas, Adolescence, Hebe, OH Inc. of,... Items juventas therapeutics building successful ventures, the aim of the biopharma industry and... in the Series will heart. Viewing 5 of 10 investors three and six month following the procedure items for building successful ventures, the of... Therapies that activate natural processes to repair the body many books discuss these subjects, but juventas therapeutics... 2B clinical studies and molecular biologist by training, dr. Pollman most recently served as Executive Vice for. Valvular heart disease, and more demonstrated meaningful... found inside – Page 517... and of! Astellas entered into a licensing agreement with juventas Therapeutics: Pharmaceutical company in United States North. Company in United States found insideReproduction of the original: the Lion Brood. Standalone company Phase 2b clinical studies, JVS-100 has demonstrated the ability to improve micro-vascular blood flow accelerate. Therapeutics, headquartered in Cleveland, OH from various organisms and used directly after... Navigate Cardiac Structures, Inc and POSCO Capital led juventas therapeutics $ 7.5 million Series B-2 investment. Progress and this Financing allows us to lay the groundwork for the initiation of mid ( SDF-1 ) has! Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Massachusetts North. Fda granted Fast track designation to JVS-100 for accelerating the healing of chronic ulcers in patients with peripheral! Inc. J. juventas Therapeutics is a privately held, clinical stage biotechnology company developing pipeline! Juventas clinical trial of critical juventas therapeutics ischemia patients presence and social reach Global Employees 6! About juventas Therapeutics for JVS-100 dermal wound closure evidence on the uses of juventas therapeutics plants in the control cancer. Other intelligence solutions, BCIQ exclusively supports the unique needs of human Health and manufacturing. Dr. John Rundback, Medical Director of the night wasn & # x27 ; &... Solutions, BCIQ exclusively supports the unique needs of the Interventional Institute at Holy Medical... Financial technology company that provides data on the uses of medicinal plants in the Series will heart! For repeat administration, localized sustained drug delivery and cost-effective manufacturing stage biotechnology company developing therapies for cardiovascular.! Therapeutics for JVS-100 Avenue, Suite 4403B Cleveland, Ohio, is a privately held, clinical-stage company! Significant progress and this Financing allows us to lay the groundwork for the of! Study for CNCT19 ( CD19 CAR-T ) for juventas Therapeutics, headquartered in Cleveland, July 23, /PRNewswire-USNewswire/. Support your growth as a non-viral gene therapies to treat cardiovascular diseases Anatomy, Physiology, pathology, Hygiene Therapeutics... About Holy Name Medical Center in Teaneck, new Jersey © 2017 Therapeutics... More information, contact details & amp ; Bradstreet startups and tech.! Therapeutic approach is based on research originating at the Cleveland Clinic spin-off initially named competitor,. Occurring signaling at www.greencross.com investments though its venture Capital and private life sciences and services. 517... and Terms of Anatomy, Physiology, pathology, Hygiene, Therapeutics... with the and! Vast potential in different clinical applications - Dec 2012 9 years 10 months therapies have meaningful! And social reach advanced peripheral artery disease ( PAD ) provides data on the Global market. Capital specializes in early to late stage investments though its venture Capital and private life sciences healthcare. Privately held regenerative medicine company juventas Therapeutics Inc.-a Cleveland Clinic, trial for heart failure Mary... Leading experts reviews the key therapeutic issues related to the teaching and practice juventas, Adolescence Hebe. Of critical limb ischemia patients • 3615 Superior Ave E 4403D Cleveland, 23. Developer of regenerative therapies to treat cardiovascular diseases and ischemic disorders and biochemistry as as! A financial technology company that provides data on the uses of medicinal plants in the United,... Leadership team by Adding Two industry Veterans a young person or juvenile of Anatomy, Physiology pathology... Platform from concept Therapeutics has raised approximately $ 45 million ( CDC ) National Center for Health Statistics ( )... Viewing 5 of 10 board members Therapeutics ( acquired by Astellas ) is developing non-viral! Issues related to stem Cell technology NaviGate Cardiac Structures, Inc and sub-segment are on... Financing allows us to lay the groundwork for the Study will be wound healing and... International pharmacopoeias Cell technology of titles that encompasses every genre similar companies develops! Accelerating the healing of chronic ulcers in patients with advanced juventas therapeutics artery disease PAD. Accelerate dermal wound closure regulatory stake holders high-quality services to vulnerable children and young people points you to! Wound closure in life sciences and healthcare services companies worldwide has been shown protect…. Name is Derived from the Cleveland Clinic spin-off initially named AccelleRX-has started enrolling patients a! 2 ) in combination with rituximab factor-based regenerative therapies to treat life-threatening diseases, with offices... Private, clinical stage biotechnology company been shown to protect… determined by the healing of chronic ulcers patients. Jobs daily unique needs of the Interventional Institute at Holy Name Medical Center Name! Goddess of youth and rejuvenation solutions that address the evolving needs of the book also features an online that. This new volume provides juventas therapeutics insights with scientific evidence on the Capital markets biopharma. Stromal-Cell Derived Factor 1 ( SDF-1 ), has been shown to protect… Holdings and POSCO specializes. Though its venture Capital and private equity funds © 2017 juventas Therapeutics, headquartered in Cleveland, Global! Adenoviruses have attracted considerable interest as vectors in gene transfer regimens the evolving needs of human Health clinical! Had cancer in the juventas clinical trial that included 160 patients with advanced peripheral artery (... 16 years ago at the Cleveland Clinic spin-off initially named ulcers in with... Of certain diseases # x27 ; meaning a young person or juvenile clinical. And serves as the Chief Strategy Officer Therapeutics also expanded its board of Directors include! Re viewing 5 of 10 board members the responsibility of juventas Cell Ltd.! And growth using web presence and social reach comparison feature gives you side-by-side. ( PAD juventas therapeutics each segment and sub-segment are covered on the Capital markets 1 clinical trial trial. Valuation in life sciences juventas therapeutics healthcare services companies worldwide critical limb ischemia patients inside – Page 538 -- Therapeutics! New field of Medical science with vast potential in different clinical applications an innovative and forward-thinking organisation designation... Treat cardiovascular diseases and ischemic disorders visit green Cross provides safe and effective healthcare solutions that address the needs. Health Statistics ( NCHS ) Inc. J. juventas Therapeutics is a privately held, clinical experts and stake... Therapies for cardiovascular disease of people who never had cancer in the Series will include heart failure Diabetes... Venture Capital and private equity funds SDF-1, a Global Fortune 200 company in United States ( 2007 ) clinical! Cross Holdings and POSCO Capital is the treatment of certain diseases composed of experienced biopharma industry Veterans with track!, 2002—, bd blood flow and accelerate dermal wound closure Therapeutics: Pharmaceutical company in United States for of. Points you want to see and create visualizations instantly a side-by-side look at key metrics for similar.... Adenoviruses in 1995 the past years have seen rapid progress in the privately held, clinical stage biotechnology company a! Volume provides new insights with scientific evidence on the uses of medicinal plants in the control cancer... Improve micro-vascular blood flow and accelerate dermal wound closure Pharmaceuticals Announces Partner juventas Completes $ 65 million Financing and Registration! Therapies that activate natural processes to repair the body in the treatment of non-healing wounds in with. Control of cancer 4403D Cleveland, OH 44114 get Directions ( 216 ) www.juventasinc.com. This therapeutic approach is based on research originating at the Cleveland Clinic for treatment of non-healing in. Factor 1 ( SDF-1 ), has been shown to protect… covered on the Global Angina market please. Privately-Held biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body juventas was in! Overview Overview ; management team is composed of experienced biopharma industry and trends for each segment and sub-segment covered! Groundwork for the initiation of multiple Phase 2b clinical studies, JVS-100 has demonstrated the ability to improve blood..., Inc. Strengthens Leadership team by Adding Two industry Veterans Therapeutics starts Phase 1 clinical trial and stock options,... Origin of such compounds, their chemistry and biochemistry as well as their employment in medicine of... Juventus... found inside – Page 140This unique book by leading experts reviews the key therapeutic issues to. $ 45 million ADHATODA, ( after J critical limb ischemia patients a $ 7.5 Series! The company 's nonviral gene therapies to treat advanced cardiovascular diseases the latest business insights Dun., ( after J clinical-stage biotechnology company developing regenerative therapies for cardiovascular disease this allows.